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Differences in anatomy and outcomes in patients
treated with open mesenteric revascularization
before and after the endovascular era
Evan J. Ryer, MD,a Gustavo S. Oderich, MD,a Thomas C. Bower, MD,a Thanila A. Macedo, MD,b
Terri J. Vrtiska, MD,b Audra A. Duncan, MD,a Manju Kalra, MBBS,a and
Peter Gloviczki, MD,a Rochester, Minn
Objective: To compare the clinical characteristics, anatomy, and outcomes of patients treated with open mesenteric
revascularization (OR) for chronic mesenteric ischemia (CMI) before and after the preferential use of endovascular
revascularization (ER).
Methods: We reviewed a prospective database of 257 patients treated for CMI with OR or ER from 1998 to 2009.
Treatment trends were analyzed to identify changes in practice paradigm. Prior to 2002, ORwas used in 58 of 81 patients
(72%). Since 2002, ER surpassed OR as the most common treatment option; OR was indicated in 58 of 176 patients
(33%) who either failed ER or had unfavorable lesions for stent placement. We analyzed differences in clinical data,
anatomical characteristics, and outcomes in 116 patients treated with OR before (Pre-Endo, n  58) and after 2002
(Post-Endo, n  58). Anatomical characteristics were determined by a blinded investigator using conventional
angiography, magnetic resonance angiography, and computed tomography angiography with centerline of flowmeasure-
ments.
Results: Both groups had similar demographics, risk factors, and clinical presentation, with the exception of higher (P <
.05) rates of hypertension, hyperlipidemia, cardiac interventions, dysrhythmias, and higher comorbidity scores in the
Post-Endo group. This group also hadmore extensive mesenteric artery disease, including higher incidence of three-vessel
involvement (76% vs 57%; P .048) and superior mesenteric artery (SMA) occlusion (67% vs 41%;P .005). There were
no differences (P > .05) in the number of vessels revascularized (1.8  0.4 vs 1.7  0.5) and in graft configuration
(antegrade, 91% vs 78%; retrograde, 9% vs 22%; two-vessel, 69% vs 81%) in the Pre- and Post-Endo groups, respectively.
There were no differences in operative mortality (1.7% vs 3.4%), morbidity (43% vs 53%), length of stay (12  1 vs 12 
1 days), and immediate symptom improvement (88% vs 86%) in the Pre- and Post-Endo groups, respectively. Mean
follow-up was 57  6 months for patients treated before 2002 and 29  6 months for those treated after 2002 (P 
.0001). At 5 years, primary and secondary patency rates and recurrence-free survival were 82%, 86%, and 84% in the
Pre-Endo and 81%, 82%, and 76% in the Post-Endo groups (P > .05).
Conclusion: OR has been used in approximately one-third of patients treated for CMI since 2002. Despite more
comorbidities and more extensive mesenteric artery disease in patients now treated with OR, outcomes have not changed
compared with those operated prior to the preferential use of mesenteric stents before 2002. (J Vasc Surg 2011;53:
1611-8.)
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eNational data indicate that endovascular mesenteric re-
vascularization (ER) has decreased in-hospital mortality and
shortened length of stay when compared to open surgery.1,2
Furthermore, mesenteric angioplasty and stenting is associ-
atedwith significantly lessmorbidity while providing excellent
symptom improvement in patients with chronic mesenteric
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doi:10.1016/j.jvs.2011.01.054schemia (CMI).3-6 However, several studies have shown that
R is less durable when compared with open mesenteric
evascularization (OR), with higher rates of restenosis, symp-
om recurrence, and reintervention.3,4 A recent systematic
eview of the literature has demonstrated improved primary
atency and long-term clinical improvement for OR, with
imilar secondary patency rates for both methods of treat-
ent.5 Despite the lack of prospective randomized data com-
aring the two modalities of treatment, ER has been widely
dopted as first-line therapy, resulting in a decline in the
umber of ORs.1,6
Mesenteric artery stents are best suited for patients with
hort-length stenoses that are not severely calcified. Long
tenoses, occlusions, or lesions with extensive calcification or
hrombus are technicallymore difficult to treat with stents.6 It
s logical to postulate that OR currently is being used in
atients who are not ideal candidates for stents because of less
avorable anatomic features. Whether results of OR in the
ndovascular era match the historical results before the pref-
rential use of stents remains to bedetermined.The aimof this
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June 20111612 Ryer et alstudy was to describe differences in clinical characteristics,
anatomical measurements, and outcomes in patients treated
for CMI with OR before and after the preferential use of
mesenteric stents.
METHODS
The study was approved by the Institutional Review
Board of the Mayo Clinic. A prospective database of 257
patients treated for CMI with OR or ER from 1998 to
2009 was reviewed. We included in the study 116 consec-
utive patients treated for CMI with OR. Of these, 82 were
included in our previous report.3 Patients with acute mes-
enteric ischemia, median arcuate ligament syndrome, mes-
enteric vasculitis, or asymptomatic occlusive disease were
excluded from the analysis.
Treatment trends between OR and ER were analyzed
to identify changes in practice paradigm (Fig 1). In the
period between 1998 and 2002, OR was used in 58 of 81
patients (72%), with a progressive decline in utilization of
OR from 85% in 1998 to 60% in 2001. Since 2002, ER
surpassed OR as the most common type of treatment for
CMI. The number of ER procedures averaged 15 per
year, corresponding to 50% of the revascularizations in
2002 and 67% in 2009. Since 2002, ER was used as
first-line therapy with OR used in 58 of 176 patients (33%)
because ER was not possible, failed, or the anatomy was
considered unfavorable for ER because of mesenteric oc-
clusion, severe calcification, or long-segment stenosis.
Given the preferential use of ER at our institution after
2002, this year was chosen as the dividing line between the
“pre-endovascular era” (Pre-Endo) and the “post-endovas-
cular era” (Post-Endo). Demographics, clinical character-
istics, and radiologic and operative data were obtained from
the medical records. Operative risk was assessed using the
Society for Vascular Surgery/American Association for
Vascular Surgery (SVS/AAVS) Comorbidity Severity
Score.7 Patency was evaluated with duplex ultrasound
(DUS). Computed tomography (computed tomography
Fig 1. Distribution of open surgical (Open) and endovascular
(Endo) revascularizations for chronic mesenteric ischemia from
1990 to 2009.angiography [CTA]), magnetic resonance angiography nMRA), or biplane mesenteric angiography was obtained if
he DUS failed to visualize the bypass graft or to further
valuate restenosis. Follow-up consisted of clinical exami-
ation and DUS every 6 months during the first postoper-
tive year and annually thereafter. Restenosis was defined as
eak systolic velocities 300 cm/s with end-diastolic ve-
ocities 70 cm/s, or a graft peak systolic velocity 40
m/s documented by DUS.
Anatomical characteristics of the celiac axis (CA), supe-
ior mesenteric artery (SMA), inferior mesenteric artery
IMA), and aorta were analyzed by a blinded investigator
sing conventional angiography, MRA, and CTA. Addi-
ional measurements were made from reconstructed CTA
mages using the Aquarius three-dimensional workstation
ith centerline of flow measurements whenever possible
TeraRecon, Inc, version 3.7.0.7, San Mateo, Calif).
Statistical analysis. Data were analyzed using SVS
eporting standards.8 Outcomes were analyzed in patients
onsidered low- and high-risk for open mesenteric revascu-
arization. The definition of high-risk criterion was vali-
ated on a previous publication and included age 80
ears, FEV1  800 mL or diffusion capacity for carbon
onoxide 50% of predicted, home oxygen therapy, left
entricular function 25%, New York Heart Association
NYHA) class III or IV angina pectoris, cardiac stress test
ositive for myocardial ischemia, myocardial infarction
90 days or baseline Cr 3.0 mg/dL.3 End points were
ortality, morbidity, symptom improvement, survival, pa-
ency rates, and recurrence-free survival and reinterven-
ions. Survival and patency data were analyzed using
aplan-Meier estimates, and differences were determined
y the log-rank test. The multivariate Cox proportional
azard model was used to identify independent predictors
f mortality, restenoses, and symptom recurrence requiring
eintervention. The Pearson 2 or Fisher’s exact test was
sed for analysis of categoric variables. Differences between
eans were tested with two-sided t test, the Wilcoxon
ank-sum test, or the Mann-Whitney test. A P value of
.05 determined statistical significance.
ESULTS
Clinical characteristics. There were 88 female and 28
ale patients with mean age of 63  12 years. Fifty-eight
atients were treated in the Pre-Endo and 58 in the Post-
ndo eras. Both groups had similar demographics and
ardiovascular risk factors (Table I), with the exception of
igher incidences of hypertension (67% vs 86%; P  .02),
yperlipidemia (36% vs 75%; P .0001), prior intervention
or coronary artery disease (14% vs 29%; P  .04), cardiac
ysrhythmia (7% vs 28%; P .003), and higher SVS/AAVS
omorbidity Severity Scores7 (5.0 vs 7.0; P .027) in the
ost-Endo group.
All patients had abdominal pain and/or weight loss.
linical presentation was similar in both groups (Table II,
nline only), except for greater frequency of food fear (45%
s 71%; P  .005), postprandial abdominal pain (72% vs
8%; P  .03), and need for preoperative total parenteral
utrition (2% vs 10%; P  .04) in the Post-Endo group.
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Volume 53, Number 6 Ryer et al 1613Anatomical measurements. Imaging of the mesen-
teric vasculature varied between the two periods (Table
III). Nearly all patients in the Pre-Endo group (97%) had
conventional angiography, compared with 57% in the Post-
Table I. Demographics, cardiovascular risk factors, and pe
mesenteric ischemia treated with open mesenteric artery re
Endo) the preferential use of mesenteric stents
Variable
Pre-E
n
Age (mean  SD) 6
Female gender
Hypertension
Smoking history
Peripheral arterial disease
Hyperlipidemia
Diabetes
Congestive heart failure
Prior chronic mesenteric ischemia intervention
Coronary artery disease
Prior coronary artery disease intervention
Dysrhythmia
Prior myocardial infarction
Ejection fraction % 6
Chronic renal insufficiency (Cr  1.5 mg/dL)
Chronic obstructive pulmonary disease
Society of Vascular Surgery comorbidity score
ASA score
Follow-up (months) 5
ASA, American Society of Anesthesiology.
Bold entries indicate statistical significance, P .05.
Table III. Preoperative imaging and anatomic features of
open mesenteric artery revascularization before (Pre-Endo)
stents
Variable
Pre-Endo (Gr
n  58 (
Preoperative imaging
Angiography 56 (97
Ultrasound 38 (66
Computed tomography 32 (55
Magnetic resonance angiography 7 (12
Anatomic features
Celiac axis
Mild (stenosis  40%) 3 (5)
Moderate (stenosis 40%-70%) 13 (22
Severe (stenosis  70%) 27 (47
Occlusion 15 (26
Superior mesenteric artery
Mild (stenosis  40%) 2 (3)
Moderate (stenosis 40%-70%) 6 (10
Severe (stenosis  70%) 26 (45
Occlusion 24 (42
Inferior mesenteric artery
Mild (stenosis  40%) 25 (43
Moderate (stenosis 40%-70%) 4 (7)
Severe (stenosis  70%) 16 (28
Occlusion 13 (22
Three-vessel disease 33 (57
Bold entries indicate statistical significance, P .05.Endo group (P  .0001). The use of CTA increased from i5% before 2002 to 88% after 2002 (P .0001), andMRA
rom 12% to 33% (P  .007). Patients treated with OR in
he Post-Endo era had more extensive mesenteric artery
isease (Table III). Three-vessel involvement was present
erative risk assessment in 116 patients with chronic
larization ischemia before (Pre-Endo) and after (Post-
Group A)
8 (%)
Post-Endo (Group B)
n  58 (%) P value
12 63.2  13 .85
76) 44 (76) 1.0
67) 46 (86) .02
79) 46 (79) 1.0
39) 28 (48) .35
36) 44 (76) .0001
10) 13 (22) .08
5) 5 (9) .5
7) 6 (10) .5
31) 25 (43) .2
14) 17 (29) .04
7) 16 (28) .003
21) 13 (22) .8
9 58.2  10 .3
17) 10 (17) 1.0
15) 14 (24) .2
0.6 7.0  0.7 .027
0.1 3.0  0.1 .2
6 28.8  6 .0001
patients with chronic mesenteric ischemia treated with
after (Post-Endo) the preferential use of mesenteric
) Post-Endo (Group B)
n  58 (%) P value
33 (57) .0001
30 (52) .13
51 (88) .0001
19 (33) .007
3 (5) 1.0
9 (16) .3
28 (48) .9
18 (31) .7
1 (2) .6
2 (3) .3
16 (28) .08
39 (67) .005
14 (24) .048
11 (19) .09
19 (33) .7
14 (24) .8
44 (76) .048riop
vascu
ndo (
 5
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June 20111614 Ryer et alin the Post-Endo group (P  .048). The latter group also
had a higher incidence of SMA occlusions (41% vs 67%; P
.005) but similar degree of atherosclerotic disease in the CA
and IMA.
Mesenteric revascularization. Two hundred three
vessels were revascularized for the entire cohort (Table IV).
The number of vessels treated per patient was similar in the
Pre-Endo (1.8  0.4) and Post-Endo era (1.7  0.5; P 
.09). Themost common graft configuration in both groups
was a supraceliac aorta to celiac and SMA bypass, which was
used in 88 of the 116 patients (76%). Concurrent aortic
reconstruction was required in nine patients (8%) to pro-
vide a source of inflow for the mesenteric bypass. Com-
pared with patients treated in the Pre-Endo era, those in the
Post-Endo group less often underwent antegrade bypass
(78% vs 91%) or two-vessel revascularizations (69% vs 81%),
and more often had retrograde grafts based from the iliac
arteries (22% vs 9%) and isolated SMA revascularizations
(29% vs 19%). None of these differences were statistically
significant. Overall, 28 patients underwent single-vessel
revascularization, the majority being in a retrograde orien-
tation, and 88 patients underwent two-vessel revasculariza-
tion. Patients undergoing single-vessel revascularization
were older (68.4 vs 61.8 years; P  .0125) and had a
greater SVS comorbidity score (8.5 vs 5.2; P  .0015).
Early mortality and morbidity. There were three
30-day operative deaths (2.5%), one in the Pre-Endo
(1.7%) and two (3.4%) in the Post-Endo group (P .6). All
hospital deaths occurred in patients older than 70 years,
and the average SVS/AAVS score was 12.0. Causes of
death were acute graft thrombosis, mesenteric ischemia,
and intra-abdominal sepsis in the patient treated in the
Table IV. Technical details of 116 patients with chronic m
revascularization before (Pre-Endo) and after (Post-Endo)
Variable
Pre-Endo (Gr
n  58 (
Mesenteric bypass 53 (91
Bifurcated graft 43
Single graft 10
Endarterectomy/patch angioplasty 5 (9)
Endarterectomy/transposition 0 (0)
Bypass conduit
Vein 1
Polytetrafluoroethylenee 0
Polyester 52
Configuration
Antegrade 48 (91
Retrograde 5 (9)
Vessel revascularization
Celiac 47 (81
Superior mesenteric artery 56 (97
Inferior mesenteric artery 2 (3)
Single vessel 11 (19
Two vessel 47 (81
Three vessel 0 (0)
Mean number of vessels 1.8  0
Intraoperative ultrasound 35 (62Pre-Endo era, andmyocardial infarction in both Post-Endo Batients. No clinical or operative variables predicted peri-
perative mortality.
Overall, complications occurred in 58 of the 116 pa-
ients (50%), 27 patients (47%) treated in the Pre-Endo and
1 (53%) treated in the Post-Endo era (P  .5; Table V).
he mean length of stay in the intensive care unit (ICU)
nd in the hospital was 3.9 and 13.1 days for the Pre-Endo
nd 4.5 and 12.9 days for the Post-Endo groups, respec-
ively (P  .6).
Late outcomes. The mean follow-up was significantly
onger in the Pre-Endo group (57  6 months) compared
ith the Post-Endo group (29  6 months; P  .0001).
linical and imaging follow-up was available in all 113
atients who survived the initial hospitalization.
The overall 5-year survival (Fig 2, A) was not signifi-
antly different between the Pre-Endo (84  2%) and
ost-Endo groups (78  2%; P .65). There were 19 late
eaths. The cause of death was not determined in nine
atients, but there was no record of abdominal symptoms
t the time of death. Known causes of death were myocar-
ial infarction in five patients, malignancy in four, and
troke in one. Factors associated with decreased survival by
nivariate analysis included age (P  .003), peripheral
rterial disease (P  .03), prior myocardial infarction (P 
003), congestive heart failure (CHF; P  .03), and prior
oronary intervention (P  .009). Independent predictors
f late mortality by multivariable analysis were CHF (haz-
rd ratio [HR], 7.46; 95% confidence interval [CI], 1.94 to
8.7; P  .003) and prior coronary intervention (HR,
.53; 95% CI, 1.30-9.6; P  .01; Table VI, online only).
Freedom from recurrent symptoms at 5 years was 84%
n the Pre-Endo and 76% in the Post-Endo groups (Fig 2,
teric ischemia treated with open mesenteric artery
referential use of mesenteric stents
) Post-Endo (Group B)
n  58 (%) P value
55 (95) .7
45 .8
10 1.0
2 (3) .4
1 (2) .3
2 .6
0 1.0
53 .8
43 (78) .1
12 (22) .1
37 (66) .06
58 (100) .5
3 (5) .6
17 (29) .3
40 (69) .2
1 (2) .3
1.7  0.5 .09
44 (76) .1esen
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Volume 53, Number 6 Ryer et al 1615inal pain and corresponding findings of stenosis or occlu-
sion on follow-up imaging, including nine (16%) in the
pre-Endo and seven (10%) in the Post-Endo groups. In the
Pre-Endo group, symptom recurrence occurred in seven
patients
who had bifurcated aorto-to-celiac and SMA bypass, and in
two who had isolated SMA reconstruction with endarter-
ectomy or bypass. Of the seven patients with recurrence
after bifurcated grafts, six had high-grade stenosis or occlu-
sion of the SMA limb or both limbs, and the other had
isolated CA limb occlusion with a patent SMA limb. Treat-
ment was redo OR in seven patients and mesenteric stent
placement in two. In the Post-Endo group, all seven pa-
tients with symptom recurrence had thrombosis of the
SMA limb, including six with bifurcated grafts. Treatment
in this group was thrombolysis and mesenteric stent place-
ment in four patients and open surgical thrombectomy
with patch angioplasty, iliac-SMA bypass, or redo bifur-
cated supraceliac bypass graft in one patient each. Extent of
disease, number of affected vessels, and type of revascular-
ization (single- vs two-vessel, antegrade vs retrograde) were
not associated with increased risk of recurrence (Table VI,
Table V. Early periprocedural complications in 116 patien
mesenteric artery revascularization before (Pre-Endo) and
Variable
Pre-End
n 
30-day mortality
Mean hospital stay 13.1 
Mean intensive care unit stay 3.9 
Any complication 2
Total complications
Cardiac complications
Myocardial infarction
Arrhythmia
Congestive heart failure
Pulmonary complications 1
Pneumonia
Pneumothorax
Respiratory failure
Pulmonary embolism
Chylothorax
Acute respiratory distress syndrome
Renal complications
Acute renal failure
Dialysis
Urinary tract infection
Neuro (transient ischemic attack/stroke)
Gastrointestinal complications
Prolonged ileus
Gastrointestinal bleeding
Pancreatitis
Clostridium difficile colitis
Partial small bowel obstruction
Surgical complications
Mesenteric artery/graft thrombosis
Re-exploration for bleeding
Abdominal compartment syndrome
Surgical site infection
Splenic injury requiring splenectomyonline only). tOne patient with asymptomatic celiac limb restenosis
nderwent percutaneous angioplasty and two patients
ith asymptomatic SMA limb stenosis were treated with
ndovascular or open redo surgery. Two patients with
ccluded celiac grafts and one occluded SMA graft had
o symptoms and were observed. There were no surveil-
ance studies in these three patients that indicated im-
ending graft occlusion. Five-year primary and second-
ry patency rates for CA reconstructions were 87% and
2% in the Pre-Endo group, and 84% and 84% in the
ost-Endo group (Fig 3, A and B). For SMA reconstruc-
ions, 5-year primary and secondary patency rates
ere 79% and 82% and 80% and 82%, respectively
Fig 4, A and B).
Effect of high-risk criteria. Twenty-seven patients
22%) were classified as high-risk for revascularization,
ncluding 10 patients (17%) treated in the Pre-Endo and
7 (30%) in the Post-Endo era (P  .19). Complications
ccurred in 42 of the 89 low-risk (47%) and in 15 of 27
igh risk patients (56%; P  .5). When comparing early
ortality, there were two deaths among high-risk pa-
ith chronic mesenteric ischemia treated with open
(Post-Endo) the preferential use of mesenteric stents
oup A)
%)
Post-Endo (Group B)
n  58 (%) P value
2 (3) .6
ays 12.3  1 Days .6
Days 4.5  0.8 Days .5
) 31 (53) .5
40 1.0
) 5 (13) .7
3
1
1
) 10 (25) .8
4
0
4
0
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) 5 (13) .8
1
1
3
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June 20111616 Ryer et al.13). Five-year survival was significantly higher in the
low-risk (84%) compared with the high-risk groups
(70%; P  .03). However, there were no differences in
5-year primary (80 vs 87%; P  .37) and secondary
patency (84% vs 87%; P  .67) in both groups, respec-
tively.
DISCUSSION
The main objective of this study was to elucidate
whether clinical outcomes and patency rates of contempo-
rary open mesenteric reconstructions were equivalent to
those done in the pre-endovascular era. In this retrospec-
tive single-institution experience, we found no difference in
early and late outcomes. The incidence of complications
(50%) and mean length of hospitalization (12-13 days)
remain significant for open surgery and have not changed
since the preferential use of mesenteric stenting. In addi-
tion, despite more cardiovascular risk factors, higher co-
morbidity scores, and more challenging anatomy, these
procedures continue to be highly effective, providing dura-
ble symptom relief with relatively low restenoses and recur-
rence rates.
Over the past decade, mesenteric artery stenting has
grown in applicability for treatment of patients with
Fig 2. Kaplan-Meier estimates of overall patient survival and re-
currence-free survival in 116 patients treated with open mesenteric
revascularizations for chronic mesenteric ischemia before (Pre-
endo) and after (Post-endo) the preferential use of mesenteric stents.chronic mesenteric ischemia at most institutions, including Sur own. Once reserved only for high-risk patients, endo-
ascular treatment has gained favor as first-line therapy for
ost patients, relegating open reconstructions for those
ho have failed stenting or have anatomy unsuitable for it.
he enthusiasm for endovascular techniques may be ex-
lained by several factors, including high mortality rates of
ypass in some recent reports, the limited experience of
ascular surgeons in performing these reconstructions, and
he excellent early results of endovascular therapy.9-11 In
ontrast, we have previously reported exceptionally low
ortality rates (0.9%) for open mesenteric reconstructions
n good-risk patients, showing that these reconstructions
an be performed safely by experienced surgeons. Never-
heless, these results are not easily reproduced in the vascu-
ar community, as evidenced by a recent analysis of the New
ork State Health Department database showing a mortal-
ty rate of 20% following open revascularization for chronic
esenteric ischemia.12 These discrepancies likely reflect
ifferences in outcomes between large and low-volume
enters and the impact of a multidisciplinary team to select
he optimal treatment modality for each patient, whether
pen, endovascular, or a hybrid approach.
The changes in treatment selection in our institution
ere nearly identical to the national trends described by
ig 3. Kaplan-Meier estimates of primary and secondary celiac
raft limb patency in 86 patients treated with open mesenteric
evascularizations for chronic mesenteric ischemia before (Pre-
ndo) and after (Post-endo) the preferential use of mesenteric stents.chemerhorn and associates.1 Since 2002, we have ob-
s
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Volume 53, Number 6 Ryer et al 1617served a dramatic shift from the majority of patients under-
going open mesenteric revascularization to over 70% of our
patients currently being treated with mesenteric stents.
This study highlights important changes in clinical charac-
teristics and anatomy for patients undergoing open mesen-
teric reconstructions over the last decade. Since 2002, at
our institution, patients treated with OR had higher inci-
dences of hypertension, hyperlipidemia, cardiac interven-
tions, dysrhythmias, prior mesenteric interventions, and
standardized comorbidity scores, findings similar to those
of national data.1 In addition, these patients had more
challenging anatomy, often had multivessel involvement,
and had more SMA occlusions than those treated by open
techniques in the pre-endovascular era. Nonetheless, de-
spite these adverse characteristics, operativemortality at our
institution remained low and was unchanged compared
with the results achieved in the pre-endovascular era. Fi-
nally, our results compare favorably with other reports of
large tertiary care centers and with national trends.1
A few changes in our operative approach may have
accounted for the low operative mortality rate achieved in
the postendovascular era, despite less favorable clinical and
anatomical characteristics. We learned from our previous
Fig 4. Kaplan-Meier estimates of primary and secondary superior
mesenteric artery graft limb patency in 115 patients treated with
openmesenteric revascularizations for chronic mesenteric ischemia
before (Pre-endo) and after (Post-endo) the preferential use of
mesenteric stents. SMA, Superior mesenteric artery.reports that mortality rates are higher (6.7%) for recon- ftructions done in high-risk patients (age 80, FEV1 
00 mL, diffusion capacity for carbon monoxide 50%,
esting pCO2  50 mm Hg, resting O2  60 mm Hg,
ome oxygen therapy, ejection fraction25%, NYHA class
II or IV angina, positive cardiac stress testing, myocardial
nfarction 90 days, or Cr 3.0) or when combined with
ortic procedures (8.6%), compared with a low mortality
ate of only 0.9% in good-risk patients.6 We avoid aortic-
ased reconstructions in high-risk patients, reserving ante-
rade aortoceliac-SMA bypasses for good-risk patients with
ultivessel involvement and who do not have excessive
upraceliac aortic calcification. This study reflects some of
hese changes; since 2002, we have more often used iliac-
ased reconstructions and single-SMA bypasses, indicating
ur preference for selecting a less extensive form of recon-
truction in patients with poor cardiopulmonary reserve
nd who have failed or were not considered good candi-
ates for endovascular therapy. Although differences in
perative techniques did not reach statistical significance in
ur study, the number of patients was small, which may
ave resulted in type II error. Other authors have shown
hat isolated SMA bypasses based on the iliac artery are a
afe and effective, albeit a less complete option for revascu-
arization in patients with chronic mesenteric isch-
mia.6,8,13 Specifically, the Oregon group has reported an
perative mortality rate of 3% in CMI patients with imme-
iate perioperative symptom improvement in 100% for
ingle SMA revascularization based on the iliac artery.14
nother less-invasive alternative reported by the Dart-
outh group, which was not used in this study, is a hybrid
pproach with retrograde SMA stenting via midline lapa-
otomy.15
Our contemporary results compare favorably with
ther reports that have shown symptom improvement in
7% to 100% of patients treated with open surgery.16
estenoses occurred in 14% of patients, which is similar to
he rates reported by Kasirajan et al (13%).13 The 1-year
rimary and secondary patency rates in this study (93% and
5%) were similar to that reported by Atkins et al (90% and
4%).4 Moreover, our 5-year primary and secondary pa-
ency rates (81% and 84%) are comparable to those of
imenez et al (69% and 100%).17 However, it is possible
hat as endovascular therapy continues to evolve with more
iberal indications, patients in need of open mesenteric
evascularization will have more hostile anatomy or more
omorbid conditions that could adversely impact results of
pen surgery.
While there is no question about the durability of open
esenteric reconstructions, controversy continues to sur-
ound whether single- or multiple-vessel revascularizations
re recommended. Our preference has been to reconstruct
wo vessels whenever possible in lower-risk patients. We
ave previously reported and continue to find that symp-
omatic recurrence after open repair occurs when both
imbs of a bifurcated graft fail or when a single graft to the
MA became stenotic.18 In this study, we found that six of
he seven patients with symptom recurrence following bi-
urcated grafts had occlusion of the SMA or both limbs.
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June 20111618 Ryer et alThis study is novel for it is the first to evaluate the
impact of endovascular mesenteric revascularizations on
changes in clinical and anatomical characteristics and out-
comes of open mesenteric revascularization in a single
center. However, our study has several shortcomings,
which need to be discussed. First, several factors that con-
tribute to the decision on type of reconstruction (open vs
endovascular, antegrade vs retrograde, etc.) are difficult to
evaluate because of the retrospective, nonrandomized
study design. Secondly, only patients undergoing revascu-
larization were included in this analysis, and 82 patients had
been previously reported.3 Lastly, the small number of
patients in subgroups has likely introduced type II error,
and it is possible that differences in variables and outcomes
would reach statistical significance with a larger patient
population.
In summary, open mesenteric revascularization contin-
ues to have an important role in the endovascular era and
was utilized in approximately one-third of patients treated
for CMI after 2002, a significant shift in practice compared
to 72% use of open surgery prior to this. Despite more
patient comorbidities and the presence of more extensive
mesenteric disease in patients currently treated with OR,
outcomes have not changed in comparison to those
achieved prior to the preferential use of mesenteric stents.
While patient preference, decreased morbidity, and rapid
recovery will continue to drive the preferential use of endo-
vascular mesenteric revascularization, open revasculariza-
tion, when performed with low mortality, remains a dura-
ble option and should be considered the gold standard for
comparison with newer endovascular techniques.
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Volume 53, Number 6 Ryer et al 1618.e1Table II (online only). Clinical presentation in 116 patie
mesenteric artery revascularization ischemia before (Pre-En
stents
Variable
Pre-Endo (G
n  58
Symptom duration, days 377.8 
Abdominal pain 51 (8
Weight loss 41 (7
Baseline weight, kg 65.0 
Presentation weight, kg 55.6 
Absolute weight loss, kg 8.8 
Weight loss, % 14.0 
Postoperative weight, kg 60.1 
Postprandial pain 42 (7
Abdominal bruit 25 (4
Food fear 26 (4
Diarrhea 22 (3
Nausea and vomiting 43 (2
Preoperative total parenteral nutrition 1 (1
Bold entries indicate statistical significance, P .05.nts with chronic mesenteric ischemia treated with open
do) and after (Post-Endo) the preferential use of mesenteric
roup A)
(%)
Post-Endo (Group B)
n  58 (%) P value
56.4 401.4  78 .8
9) 56 (96) .08
1) 44 (76) .08
11 72.9  22 .02
14 60.9  18 .07
8 12.7  11 .04
12 17.7  17 .2
13 71.8  14.6 .12
2) 51 (88) .03
3) 23 (40) .7
5) 41 (71) .005
8) 19 (33) .7
5) 43 (25) 1.0
) 6 (10) .04
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June 20111618.e2 Ryer et alTable VI (online only). Cox proportional hazard model analysis and multivariate analysis of independent factors
associated with overall survival, symptom recurrence, and primary patency in 116 patients with chronic mesenteric
ischemia treated with open mesenteric artery revascularization before (Pre-Endo) and after (Post-Endo) the preferential
use of mesenteric stents
Variable Hazard ratio 95% CI P value
Univariate analysis
Overall survival
Age 1.09 1.04-1.14 .0003
Peripheral arterial disease 2.78 1.15-6.69 .02
Prior myocardial infarction 4.11 1.61-10.5 .003
Congestive heart failure 4.06 1.16-14.2 .03
Prior cardiac intervention 3.13 1.32-7.41 .01
Multiple anticoagulants 4.63 1.29-16.6 .02
Ejection fraction 0.94 0.91-0.99 .009
Symptom recurrence
Hypertension 0.28 0.10-0.81 .02
Coronary artery disease 0.15 0.02-1.26 .08
SMA revascularization 0.17 0.02-1.34 .1
Celiac primary patency
Hypertension 0.17 0.05-0.67 .01
Number of vessels revascularized 8.27 1.01-67.9 .047
SMA occlusion 4.06 0.85-19.5 .08
Celiac secondary patency
Number of vessels revascularized 18.0 1.49-217.9 .02
SMA occlusion 6.49 0.76-55.2 .09
SMA primary patency
Hypertension 0.33 0.13-0.84 .02
Coronary artery disease 0.12 .015-0.93 .04
Society of Vascular Surgery comorbidity score 0.68 0.47-0.99 .047
Female gender 0.97 0.94-1.01 .09
SMA secondary patency
Hypertension 0.36 0.14-0.95 .04
Age 0.97 0.94-5.43 .06
Multivariate analysis
Overall survival
Congestive heart failure 7.46 1.94-28.7 .003
Prior cardiac intervention 3.53 1.30-9.60 .01
Multiple anticoagulants 14.7 2.31-94.7 .005
Symptom recurrence
Hypertension 0.28 0.10-0.81 .02
Celiac primary patency
Hypertension 0.12 0.01-0.58 .009
SMA primary patency
Coronary artery disease 0.11 0.01-0.81 .03
CI, Confidence interval; SMA, superior mesenteric artery.
Bold entries indicate statistical significance, P .05.
